Skip to main content
Premium Trial:

Request an Annual Quote

Joel Brill, Susan Lindquist, Karen Wilson, Robert Weil, Robert Millman

Premium

Joel Brill has been named to the business development advisory board of GenoMed. Brill currently serves as chief medical officer of Predictive Health.


The Whitehead Institute said last week that Susan Lindquist will resign as president effective “on or about” Nov. 1. The institute said that Lindquist intends to focus on her laboratory and research.


Karen Wilson of Grosse Ile, Mich., whose parents both died of brain tumors, donated $2 million to the Cleveland Clinic Brain Tumor Institute, the Plain Dealer reported on Tuesday. The money will support the research of Robert Weil, associate director of laboratory research at the institute. Weil’s work focuses on the development of protein biomarkers as diagnostic and prognostic tools.


Alnylam Pharmaceuticals said this week that it has appointed Robert Millman as chief patent counsel. Millman, who has served as a consultant to Alnylam since June 2003, will be responsible for directing all aspects of the company’s intellectual property activities, said Alnylam. According to the company, Millman was most recently a freelance IP consultant for biotechnology companies, and served as interim chief patent counsel at Infinity Pharmaceuticals. He has also served as chief IP counsel at Celera Genomics, and patent counsel at Millennium Pharmaceuticals. Millman received a JD from Washington College of Law at the American University, an MS in genetics from Washington State University, and a BS in biochemistry from the University of California, Riverside, said Alnylam.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more